Neubase therapeutics, inc. (OHRP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10
OPERATING ACTIVITIES
Net loss

-32,323

-29,975

-26,958

-9,529

-10,419

-10,574

-13,236

-12,125

-15,481

-20,986

-23,810

-25,202

-29,001

-26,596

-25,766

-23,040

-18,686

-16,744

-15,197

-14,377

-13,081

-11,707

-9,130

-7,844

-7,132

-5,456

-5,652

-3,781

-2,903

-4,023

-1,454

-2,880

-5,557

-4,302

-5,101

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Common stock issued for services

-

-

-

-

-

-

145

179

329

513

818

1,301

1,672

2,057

1,754

1,365

997

743

635

0

0

0

-

55

270

270

270

523

309

309

309

0

0

0

10

0

0

0

Warrants issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

236

485

1,177

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

719

705

741

632

272

234

181

123

0

0

0

Stock-based compensation

11,081

10,996

9,785

287

1,694

541

877

841

1,178

1,356

1,293

1,835

2,035

3,163

2,913

3,012

3,034

3,534

3,579

3,857

3,491

2,290

2,074

1,421

1,495

840

746

496

205

446

406

365

328

47

47

0

0

0

Research and development expense - license acquired

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

10

12

19

32

45

57

64

65

64

60

47

48

40

34

36

22

17

18

14

13

13

9

9

9

9

8

7

6

5

0

0

0

Amortization of intangible assets

-

-

-

-

-

-

1,114

1,116

1,119

1,120

1,120

1,121

1,121

1,124

1,124

1,124

1,124

1,123

1,138

1,155

985

726

448

168

77

77

77

78

77

78

78

0

0

0

-

-

0

0

Gain on settlement of liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss on disposal of fixed asset

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,185

1,842

1,716

-763

-2,637

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

21

0

0

0

-

-

-

-

Gain on sale of asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

70

70

0

0

0

Loss on derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

0

0

Equity in losses on equity method investment

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-103

-108

-78

-37

-10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash amortization on convertible notes

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on convertible notes

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Other prepaid expenses and current assets

169

473

386

-262

-351

-175

-310

-378

-303

-544

-657

-56

-147

-1,622

64

-708

-525

986

-7

323

316

365

-105

-216

-229

-269

-236

-336

-249

-139

-105

240

232

107

82

0

0

0

Long-term prepaid insurance

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

368

368

184

-453

-453

-453

-119

0

0

0

Accounts payable and accrued expenses

-

-

-

-

-

-1,749

-3,096

-6,107

-6,494

-67

654

2,029

4,911

2,055

3,511

2,500

1,300

1,389

1,331

1,634

649

992

-63

131

456

95

165

-80

0

-112

20

37

54

70

12

0

0

0

Net cash used in operating activities

-6,886

-5,272

-2,845

-2,845

-2,037

-5,311

-9,492

-14,170

-17,106

-17,556

-19,290

-19,048

-19,114

-18,589

-15,985

-13,162

-10,656

-11,281

-10,692

-10,061

-10,330

-6,805

-5,360

-4,706

-3,487

-3,321

-2,689

-2,285

-1,981

-2,190

-1,753

-1,642

-1,447

-1,065

-1,004

0

0

0

Cash flows from investing activities
Purchase of laboratory and office equipment

585

523

455

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

33

33

33

33

0

0

0

0

Payment of transaction costs for license acquired

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

4

6

7

8

14

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of property, equipment and intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

70

70

0

0

0

Cash paid for license acquired

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Net cash used in investing activities

-718

-656

-685

0

0

0

-

-

-

-

88

82

-7

-8

-14

0

0

0

-

-

-

-

-

-

-

-

-

-

0

0

-33

-33

-33

37

70

0

0

0

Cash flows from financing activities
Principal payment of financed insurance

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock in pre-acquisition financing, net of issuance costs

-

-

-

-

-

-

-

-

-

-

19,580

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

50

1,100

1,100

1,100

1,505

1,050

0

0

0

Repurchase of common stock

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of preferred stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Proceeds from warrants exercised for cash

-

-

-

-

-

-

270

270

270

225

118

118

131

131

26

26

13

90

80

80

140

63

260

287

5,263

5,339

5,251

7,028

3,091

3,014

2,902

1,098

0

0

0

0

0

0

Proceeds from related party payables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Repayments of related party payables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Proceeds from short-term notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-48

0

0

74

48

0

0

0

0

0

Repayments of short-term notes payable

-

-

-

-

-

-

356

300

296

261

242

233

215

215

176

204

189

212

208

202

217

194

164

127

67

71

71

65

71

67

52

30

1

6

17

0

0

0

Repayment of convertible debentures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

51

0

0

0

Net (used in) provided by financing activities

12,870

13,521

13,595

-181

386

-204

-86

13

12,707

12,697

19,456

19,422

6,761

6,761

-150

-178

-175

26,461

26,454

26,460

43,381

16,745

16,972

17,036

5,196

5,268

5,180

6,888

2,971

2,997

3,949

2,242

1,146

1,498

981

0

0

0

Net (decrease) increase in cash and cash equivalents

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET CHANGE IN CASH

-

-

-

-

-

-

-9,050

-13,643

-4,305

-4,765

254

455

-12,360

-11,836

-16,150

-13,355

-10,941

14,884

15,476

16,101

29,349

6,424

8,097

8,829

1,708

1,947

2,490

4,603

989

806

2,162

566

-334

469

47

0

0

0

Cash paid for interest

4

4

3

3

7

8

10

11

10

9

8

0

0

0

-

-

-

5

5

8

6

5

5

1

4

4

4

4

2

2

1

22

21

21

24

0

0

0

Cash paid for income taxes

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Issuance of common stock for research and development expense-licenses acquired

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrant liability issued for research and development expense- licenses acquired

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income Taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Common stock and warrants issued in advance of services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Financing of insurance premiums through issuance of short term notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

138

74

74

74

0

0

0

-

-

-

-

Settlement of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,425

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of preferred for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

Reclassification of derivative liability to permanent equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,454

0

0

0

-

-

-

-

Common stock issued to settle accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

50

50

50

50

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Noncash exercise of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Transfer of investment for dividends payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Purchase of patents for debenture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Conversion of debenture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Common stock issued to settle accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Options issued to settle accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

0

0

Stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-